Literature DB >> 1997096

Formation of interaction products of carboplatin with DNA in vitro and in cancer patients.

P M Terheggen1, A C Begg, J Y Emondt, R Dubbelman, B G Floot, L den Engelse.   

Abstract

Binding of the cytostatic drug carboplatin to DNA was studied in solution, in RIF-1 and CHO cell lines and in human buccal cells after in vitro or in situ drug exposure. Results were compared with DNA adduction by cisplatin. The rate of binding in solution, determined by atomic absorption spectroscopy, was 35 times lower for carboplatin than for cisplatin. Adduct formation in cells in vitro was determined in a quantitative immunostaining assay. Staining intensities after carboplatin treatment were at least 29 times lower than after an equimolar dose of cisplatin. For RIF-1 and CHO cells, maximum levels of carboplatin-induced DNA modification were obtained 24 h after treatment; these levels correlated with cell killing. Adduct-specific staining in buccal cells from two carboplatin-treated patients increased 5-7 fold between 0 and 14 h after infusion, reaching a maximum at 10-14 h. This strongly contrasts with buccal cells from a cisplatin-treated patient, in which the adduct-specific staining signal increased by only 23% between 0 and 6 h after infusion, and then declined. This difference in the rate of adduct formation in vivo is consistent with the in vitro data.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997096      PMCID: PMC1971771          DOI: 10.1038/bjc.1991.48

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

Review 1.  Mechanism of action of cis-dichlorodiammineplatinum(II).

Authors:  L A Zwelling; K W Kohn
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

Review 2.  Fundamental studies with cisplatin.

Authors:  B Rosenberg
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

3.  Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

Authors:  E Reed; R F Ozols; R Tarone; S H Yuspa; M C Poirier
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

4.  Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.

Authors:  M C Poirier; S J Lippard; L A Zwelling; H M Ushay; D Kerrigan; C C Thill; R M Santella; D Grunberger; S H Yuspa
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

5.  Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.

Authors:  P M Terheggen; J Y Emondt; B G Floot; R Dijkman; P I Schrier; L den Engelse; A C Begg
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

6.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

Authors:  R J Knox; F Friedlos; D A Lydall; J J Roberts
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

7.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.

Authors:  Z H Siddik; D R Newell; F E Boxall; K R Harrap
Journal:  Biochem Pharmacol       Date:  1987-06-15       Impact factor: 5.858

9.  Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.

Authors:  B D Evans; K S Raju; A H Calvert; S J Harland; E Wiltshaw
Journal:  Cancer Treat Rep       Date:  1983-11

10.  New chemistry of an old molecule: cis-[Pt(NH3)2Cl2].

Authors:  S J Lippard
Journal:  Science       Date:  1982-12-10       Impact factor: 47.728

View more
  7 in total

1.  Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding.

Authors:  Jarmila Mlcouskova; Jana Stepankova; Viktor Brabec
Journal:  J Biol Inorg Chem       Date:  2012-05-26       Impact factor: 3.358

Review 2.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.

Authors:  G Los; L Tuyt; M van Vugt; J Schornagel; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Human DNA adduct measurements: state of the art.

Authors:  M C Poirier; A Weston
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

6.  DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.

Authors:  Alessia Stornetta; Maike Zimmermann; George D Cimino; Paul T Henderson; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2017-01-03       Impact factor: 3.739

7.  Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.

Authors:  V Rantanen; S Grénman; J Kulmala; R Grénman
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.